Apretude Injection: Understanding Dosage and Administration for HIV Prevention

In the ongoing battle against HIV, advancements in prevention methods are crucial. Apretude (cabotegravir) injection represents a significant development in pre-exposure prophylaxis (PrEP), offering a long-acting option for individuals at high risk of contracting HIV. This article aims to provide a comprehensive understanding of Apretude's dosage, administration, and its role in HIV prevention, specifically tailored for an Indian audience. What is Apretude and How Does it Work? Apretude is a prescription medication containing the active ingredient cabotegravir. It is formulated as a liquid suspension intended for intramuscular injection, meaning it's injected directly into a muscle, typically in the buttock. Unlike daily oral pills, Apretude is a long-acting injectable PrEP. This means it stays in the body for an extended period, providing continuous protection against HIV. It works by blocking the virus from multiplying if exposure occurs. Who is Apretude For? Apretude is approved for use in adults and adolescents who weigh at least 35 kilograms (approximately 77 pounds). It is indicated for individuals who are at high risk of sexually acquired HIV infection. It is crucial to understand that Apretude is part of a comprehensive HIV prevention strategy, which includes regular HIV testing, counseling, and the use of condoms. It is not recommended for individuals who are already living with HIV or for children younger than 12 years old or those weighing less than 35 kg. Dosage and Administration: A Step-by-Step Guide The dosage and administration schedule for Apretude are specific and designed to ensure maximum effectiveness and safety. It's essential to follow your healthcare provider's instructions precisely. 1. Oral Lead-in Phase (Optional but Recommended) Before starting Apretude injections, your doctor may prescribe oral cabotegravir tablets (brand name Vocabria). This 'lead-in' phase, typically lasting about a month (at least 28 days), involves taking 30 mg of cabotegravir tablets once daily. The purpose of this phase is to: Assess your body's reaction to cabotegravir. Identify any potential side effects that might be bothersome or severe. Ensure that the injectable form will be well-tolerated. If you experience significant side effects during the oral phase, your doctor can adjust the treatment plan before you proceed with injections. 2. Initial Injection Phase Once you complete the oral lead-in phase (or if your doctor decides against it), you will begin receiving Apretude injections. The initial phase involves two injections given one month apart: First Injection: This is typically given on the day you finish your last oral cabotegravir tablet, or within 3 days after. Second Injection: This is given one month after the first injection. Each of these initial injections contains 600 mg of Apretude. 3. Maintenance Injection Phase After completing the first two monthly injections, you will transition to the maintenance phase. In this phase, Apretude injections are given every two months: Dosage: 600 mg injected once every 2 months. Administration Site: The injection is administered into the muscle of your buttock by a trained healthcare professional. Frequency: Every 8 weeks (2 months). What if You Miss a Dose? Missing an injection can impact the effectiveness of Apretude. If you miss your scheduled injection, it is crucial to contact your doctor immediately to discuss the best course of action. Your doctor will adjust your dosing schedule based on how late you are for your appointment. If you miss your 2-month injection by more than 7 days: Your doctor may prescribe oral cabotegravir tablets (30 mg once daily) for you to take for up to 2 months. This oral regimen will temporarily replace your missed injection. Restarting Injections: After completing the oral cabotegravir course, your doctor will test you for HIV. If the test is negative, you will restart Apretude injections. The first injection will be given on the day you finish the oral tablets or within 3 days after. Strength and Formulation Apretude comes as a liquid suspension for intramuscular injection. Each 3 milliliter (mL) dose contains 600 mg of cabotegravir. Important Considerations Before and During Treatment 1. HIV Testing Before starting Apretude injections, and regularly throughout your treatment, your doctor will conduct HIV tests. You will only receive an Apretude injection if your HIV test results are negative. This is because Apretude is a PrEP medication and is not intended to treat an existing HIV infection. 2. Potential Side Effects Like all medications, Apretude can cause side effects. The most common side effects are related to the injection site, such as pain, swelling, redness, or itching. Other potential side effects may include headache, fever, fatigue, nausea, and dizziness. Serious side effects, though rare, can occur. It is vital to discuss any concerns or unusual symptoms with your healthcare provider promptly. 3. Drug Interactions Apretude can interact with other medications. It is essential to inform your doctor about all the medicines, supplements, and herbal products you are currently taking to avoid potentially harmful interactions. When to Consult a Doctor It is crucial to consult your doctor or a qualified healthcare professional in the following situations: If you are considering Apretude for HIV prevention. If you have any questions about the dosage or administration schedule. If you miss an Apretude injection. If you experience any side effects, especially severe or persistent ones. If you think you may have been exposed to HIV. If you are pregnant, planning to become pregnant, or breastfeeding. Conclusion Apretude injection offers a valuable long-acting option for HIV prevention, particularly for individuals who may find daily oral medication challenging. Understanding the

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.